"Oncolytic Virotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
Descriptor ID |
D050130
|
MeSH Number(s) |
E02.095.601
|
Concept/Terms |
Oncolytic Virotherapy- Oncolytic Virotherapy
- Oncolytic Virotherapies
- Virotherapies, Oncolytic
- Virotherapy, Oncolytic
- Oncolytic Virus Therapy
- Oncolytic Virus Therapies
- Therapies, Oncolytic Virus
- Therapy, Oncolytic Virus
- Virus Therapies, Oncolytic
- Virus Therapy, Oncolytic
|
Below are MeSH descriptors whose meaning is more general than "Oncolytic Virotherapy".
Below are MeSH descriptors whose meaning is more specific than "Oncolytic Virotherapy".
This graph shows the total number of publications written about "Oncolytic Virotherapy" by people in this website by year, and whether "Oncolytic Virotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2007 | 1 | 0 | 1 |
2015 | 0 | 1 | 1 |
2018 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2021 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Oncolytic Virotherapy" by people in Profiles.
-
Iscaro A, Jones C, Forbes N, Mughal A, Howard FN, Janabi HA, Demiral S, Perrie Y, Essand M, Weglarz A, Cruz LJ, Lewis CE, Muthana M. Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus. Nanomedicine. 2022 02; 40:102506.
-
Muhuri M, Gao G. Oncolytic Virus Alphavirus M1: A New and Promising Weapon to Fight Cancer. Hum Gene Ther. 2021 02; 32(3-4):136-137.
-
Haines BB, Denslow A, Grzesik P, Lee JS, Farkaly T, Hewett J, Wambua D, Kong L, Behera P, Jacques J, Goshert C, Ball M, Colthart A, Finer MH, Hayes MW, Feau S, Kennedy EM, Lerner L, Qu?va C. ONCR-177, an Oncolytic HSV-1 Designed to Potently Activate Systemic Antitumor Immunity. Cancer Immunol Res. 2021 03; 9(3):291-308.
-
Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G. White paper on microbial anti-cancer therapy and prevention. J Immunother Cancer. 2018 08 06; 6(1):78.
-
Li K, Zhang H, Qiu J, Lin Y, Liang J, Xiao X, Fu L, Wang F, Cai J, Tan Y, Zhu W, Yin W, Lu B, Xing F, Tang L, Yan M, Mai J, Li Y, Chen W, Qiu P, Su X, Gao G, Tai PW, Hu J, Yan G. Activation of Cyclic Adenosine Monophosphate Pathway Increases the Sensitivity of Cancer Cells to the Oncolytic Virus M1. Mol Ther. 2016 Feb; 24(1):156-65.
-
Kuruppu D, Dorfman JD, Tanabe KK. HSV-1 viral oncolysis and molecular imaging with PET. Curr Cancer Drug Targets. 2007 Mar; 7(2):175-80.